NIAID Site Search

Sample grant application from Stephen Dewhurst, Ph.D., for exploratory with possible transition to expanded development grant (R21/R33).

Last Reviewed: April 21, 2025

Lenette Lu, M.D., Ph.D., of the Massachusetts General Hospital K08 sample application

Last Reviewed: March 31, 2025

Stephen Dewhurst, Ph.D., of the University of Rochester, R21/R33 sample application

Last Reviewed: March 31, 2025

Nico Contreras, Ph.D., of University of Arizona, F31 sample application

Last Reviewed: March 31, 2025

Lilliam Ambroggio, Ph.D., of the Cincinnati Children’s Hospital Medical Center K01 sample application

Last Reviewed: March 31, 2025

This document provides a progress report for NIAID Biodefense Research Agenda for Category B and C Priority Pathogens.

Last Reviewed: August 6, 2019

This document provides CRSs with guidance on the premature termination or suspension of a clinical trial.

Last Reviewed: October 2, 2023

This document outlines systematic evaluation of nine monogenic autoinflammatory diseases.

Last Reviewed: April 7, 2021

This document provides a progress report about the Biodefense Research Agenda for CDC Category A Agents in 2006.

Last Reviewed: August 6, 2019

This document summarizes complexities of genetic determinants that lead to antigenic differences among pandemic GII.4 noroviruses.

Last Reviewed: July 6, 2021

This document summarizes a web-based iterative analysis platform integrating pathway and network approaches.

Last Reviewed: May 4, 2021

Sample application from David Al-Adra MD, Ph.D., for NIH standard independent research project grant (K08).

Last Reviewed: September 13, 2024

7.5% of U.S. adults develop post-acute sequelae of SARS-CoV-2 infection (PASC), also known as long COVID. PASC is characterized by varying symptoms, including fatigue, shortness of breath, heart palpitations or chest pain, brain fog, insomnia, dizziness, and joint or muscle pain.

Last Reviewed: July 7, 2023

Scientists have long been aware that malaria infection is associated with high levels of autoantibodies—antibodies that recognize and attack the person’s own tissues and are associated with autoimmune disorders. NIAID researchers, along with their colleagues, have studied the molecular mechanisms of these autoantibodies. Their findings reveal the associations between malaria, human resistance to it, and autoantibodies that are linked to certain autoimmune disorders—specifically, systemic lupus erythematosus (SLE).

Published: July 5, 2024

This study is a prospective, multi-center, randomized, double blinded, placebo-controlled study of OCR treatment-discontinuation in patients with early RMS.

Lead Institution: Walter and Eliza Hall Institute of Medical Research (WEHI) Background Overall, the Asia-Pacific region has achieved impressive reductions in malaria over the last 20 years. However, the Asia-Pacific ICEMR, with funding from2017-2024, documented strongly diverging regional malaria trends: Cambodia is nearing Plasmodium falciparum elimination but is confronted with the challenge of

Last Reviewed: July 12, 2024

This page covers NIAID Human Subjects Resources. Table of Contents General Human Subjects Planning a Human Subjects Application Planning an Investigator-Initiated Clinical Trial Human Subjects Documentation Human Subjects Research Plan Data Sharing Plan Human Subjects Protocol Data and Safety Monitoring Plan Phase III Clinical Trials Target Study Enrollment IND or IDE Requirements rDNA

Last Reviewed: August 30, 2019

Sample application from Nicole Putnam, Ph.D., for National Research Service Award (NRSA) individual fellowship (F31) grants.

Last Reviewed: January 25, 2023

To show NIH reviewers your project's feasibility, your application must describe your access to needed resources such as space, equipment, and facilities.

Last Reviewed: January 8, 2025

Office of Research on Women’s Health and NIH Support for Research on Women’s Health Report of the Advisory Committee on Research on Women’s Health: Fiscal Years 2019–2020 508-compliant PDF

Last Reviewed: March 8, 2022

In the 34 years since the first observance of World AIDS Day, transformational progress has been made in the global fight against HIV/AIDS, yet challenges remain. Today, we at the National Institutes of Health reflect on the 40 million lives lost to the disease and renew our commitment to the research necessary to end the global pandemic. Innovative research led to the highly effective HIV

Published: December 1, 2022

The scientific community can learn about NIAID funding opportunities, programs, and networks to further research and encourage collaboration as well as resources provided by NIAID to advance product development. Recent publications and ways to connect with other researchers studying Lyme disease, Rocky Mountain Spotted Fever, and Crimean-Congo Hemorrhagic Fever are also available.

Last Reviewed: November 10, 2024

Jordan Report: Accelerated Development of Vaccines (2012) from NIAID includes updates on vaccine research for specific infectious diseases.

Last Reviewed: December 31, 2012

Information about Father of the NIH, Dr. Kinyoun, and his role in fighting the plague in San Francisco.

Last Reviewed: August 28, 2012

Expert articles from Jordan Report: Accelerated Development of Vaccines (2012) from NIAID

Last Reviewed: December 31, 2012